Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)

Summary

The primary purpose of this study is to evaluate the safety and tolerability of ION269 in adults with Down syndrome with evidence of brain amyloid positivity.

Timeline

Start

2024-12-20

Primary completion

2025-12-03

Completion

2025-12-03

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision to terminate study early. Decision not based on safety concerns.”

Drugs

Indications